Get the Stockscreener App
30.19
1.34%
-0.41
After Hours:
30.19
Newamsterdam Pharma Company Nv stock is traded at $30.19, with a volume of 1.16M.
It is down -1.34% in the last 24 hours and down -14.81% over the past month.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
See More
Previous Close:
$30.60
Open:
$30.55
24h Volume:
1.16M
Relative Volume:
0.98
Market Cap:
$3.53B
Revenue:
$22.57M
Net Income/Loss:
$-212.73M
P/E Ratio:
-16.73
EPS:
-1.8045
Net Cash Flow:
$-142.19M
1W Performance:
-0.63%
1M Performance:
-14.81%
6M Performance:
-11.78%
1Y Performance:
+52.86%
1-Day Range:
$29.09
$31.55
1-Week Range:
$29.09
$31.55
52-Week Range:
$17.63
$42.20
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Name
Newamsterdam Pharma Company Nv
Sector
Industry
Phone
35 206 2971
Address
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
30.19 | 3.58B | 22.57M | -212.73M | -142.19M | -1.8045 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Buy |
| Oct-20-25 | Resumed | H.C. Wainwright | Buy |
| Aug-25-25 | Initiated | Wells Fargo | Overweight |
| Jul-17-25 | Initiated | Goldman | Neutral |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jun-10-25 | Initiated | Stifel | Buy |
| Jun-04-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| May-15-24 | Initiated | TD Cowen | Buy |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-18-24 | Initiated | Guggenheim | Buy |
| Jan-16-24 | Initiated | Piper Sandler | Overweight |
| Oct-30-23 | Initiated | RBC Capital Mkts | Outperform |
View All
Newamsterdam Pharma Company Nv Stock (NAMS) Latest News
NAMSW SEC FilingsNewAmsterdam Pha 10-K, 10-Q, 8-K Forms - Stock Titan
NewAmsterdam Pharma Warrants (NAMSW) Plunge 11.78% as Sellers Dominate, Testing Key SupportVolume Weighted Price - newsline.com
NewAmsterdam Pharma Rises 3.17% as Shares Approach Resistance at $31.77Bollinger Band - newsline.com
A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Weakness - Yahoo Finance
(NAMSW) Risk Channels and Responsive Allocation - Stock Traders Daily
NewAmsterdam Pharma Company N.V.Ordinary Shares (NQ: NAMS - FinancialContent
EBIT of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026 - Insider Monkey
All eyes on NewAmsterdam Pharma earnings as pipeline advances - Investing.com
Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily
Capital World Investors holds 10.4% of NewAmsterdam Pharma (NAMS) - Stock Titan
5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller - Insider Monkey
NewAmsterdam Shareholders Approve ESPP and Governance Proposals - TipRanks
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions - The Manila Times
Oral cholesterol drug obicetrapib in multiple 2026 lipid meeting studies - Stock Titan
NewAmsterdam Pharma (NASDAQ: NAMS) shareholders back 2026 ESPP and extend share issuance powers - Stock Titan
(NAMSW) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Debt to assets ratio of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
Inventory turnover of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
EBIT per share of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
Current ratio of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
Net income before discontinued operations of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
Taxes of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June - Sahm
NewAmsterdam Pharma Stock Rises as Fresh Filing Puts Its $4.3 Billion Drug Bet in Focus - Bez Kabli
NewAmsterdam Pharma (NAMS) CAO exercises options and sells 65,000 shares - Stock Titan
NewAmsterdam Pharma Warrants (NAMSW) Rally 3.05% as Price Nears Key ResistanceOvervalued Signals - thelegaladvocate.com
[144] NewAmsterdam Pharma Co N.V. SEC Filing - Stock Titan
NewAmsterdam Pharma (NAMS) Edges Higher as Shares Test Key Resistance LevelArms Index - The Legal Advocate
Technical Reactions to NAMS Trends in Macro Strategies - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Q1 2026 Earnings: EPS Beat Reflects Cost Management Amid Pre-Revenue Phase - The Legal Advocate
NewAmsterdam Pharma Co NV (HAM:KH6) Cyclically Adjusted Pri - GuruFocus
NewAmsterdam Pharma (NAMS) Slightly Lower Amid Consolidation Near Key Support LevelsGamma Squeeze - newsline.com
NewAmsterdam Pharma Insiders Who Sold Avert US$477m Market Cap Dip - Moomoo
Bain Life Sciences trims NewAmsterdam (NAMS) holding to about 3.3% - Stock Titan
Trading the Move, Not the Narrative: (NAMS) Edition - Stock Traders Daily
Industry Analysts Just Made A Substantial Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Forecasts - Sahm
NewAmsterdam Pharma Company N.V. (NAMS) Eps Diluted (TTM) - Zacks Investment Research
NAMS: Interim PREVAIL results expected Q1 next year, with strong efficacy and broad market potential - TradingView
Piper Sandler reiterates NewAmsterdam Pharma stock rating at overweight By Investing.com - Investing.com Nigeria
TradingKey - TradingKey
Piper Sandler reiterates NewAmsterdam Pharma stock rating at overweight - Investing.com
HC Wainwright Has Negative Forecast for NAMS Q2 Earnings - MarketBeat
NewAmsterdam Pharma stock hits all-time high at 42.02 USD By Investing.com - Investing.com India
NAMS SEC FilingsNewAmsterdam Pharma Company N.V 10-K, 10-Q, 8-K Forms - Stock Titan
NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL TrialSlideshow (NASDAQ:NAMS) 2026-05-11 - Seeking Alpha
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Why NewAmsterdam Pharma (NAMS) Is Up 29.7% After Detailing Obicetrapib Phase 3 And Launch Milestones - simplywall.st
NewAmsterdam Pharma stock hits all-time high at 42.02 USD - Investing.com
Newamsterdam Pharma Company Nv Stock (NAMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Newamsterdam Pharma Company Nv Stock (NAMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kooij Louise Frederika | Chief Accounting Officer |
May 26 '26 |
Sale |
35.69 |
65,000 |
2,319,850 |
24,353 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):